Resectable Hepatocellular Carcinoma
18
3
7
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (18)
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Neoadjuvant Triple Therapy for Resectable HCC
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
Surgical Resection for Hepatocellular Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors